Related Experiment Video

Updated: Aug 8, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Cell cycle arrest and apoptotic induction in LNCaP cells by MCS-C2, novel cyclin-dependent kinase inhibitor, through

Hae Young Park1, Min Kyoung Kim, Sang-Ik Moon

  • 1Department of Urology, Hanyang University College of Medicine, Seoul 133-791, Korea.

Cancer Science
|April 25, 2006
PubMed

Insights

MCS-C2, a novel pyrrolo[2,3-d]pyrimidine nucleoside analog, effectively inhibits human prostate cancer cell proliferation. It induces G1-phase cell cycle arrest and apoptosis by upregulating p53 and p21WAF1/CIP1.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Prostate cancer remains a significant health concern with ongoing research for novel therapeutic agents.
  • Pyrrolo[2,3-d]pyrimidine nucleosides, like toyocamycin and sangivamycin, exhibit cytotoxic properties.
  • Understanding the mechanisms of novel analogs is crucial for developing targeted cancer therapies.

Purpose of the Study:

  • To investigate the antiproliferative and apoptotic effects of MCS-C2, a novel pyrrolo[2,3-d]pyrimidine nucleoside analog.
  • To elucidate the cell cycle regulatory mechanisms underlying MCS-C2's action in human prostate cancer LNCaP cells.

Main Methods:

  • Treatment of LNCaP cells with varying concentrations and durations of MCS-C2.
  • Cell proliferation assays to assess growth inhibition.
  • Nuclear DAPI staining to detect apoptotic morphological changes.
  • Western blot analysis to evaluate the phosphorylation of p53 and expression of p21WAF1/CIP1.

Main Results:

  • MCS-C2 demonstrated time- and dose-dependent inhibition of LNCaP cell proliferation.
  • MCS-C2 induced significant apoptosis, evidenced by nuclear DAPI staining.
  • MCS-C2 caused G1-phase cell cycle arrest.
  • Upregulation of phosphorylated p53 (Ser-15) and p21WAF1/CIP1 was observed.

Conclusions:

  • MCS-C2 exhibits potent antiproliferative and pro-apoptotic effects on human prostate cancer LNCaP cells.
  • The mechanism involves G1-phase cell cycle arrest mediated by the p53/p21WAF1/CIP1 pathway.
  • MCS-C2 represents a promising therapeutic candidate for prostate cancer treatment.

More Related Videos

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...